BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 969 filers reported holding BAXTER INTL INC in Q3 2017. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $1,155,000 | -17.4% | 18,400 | -20.3% | 0.21% | -18.4% |
| Q2 2017 | $1,398,000 | -29.8% | 23,094 | -39.8% | 0.26% | -33.1% |
| Q1 2017 | $1,991,000 | +110.7% | 38,383 | +80.0% | 0.39% | +63.2% |
| Q4 2016 | $945,000 | +45.4% | 21,319 | +56.0% | 0.24% | +21.3% |
| Q3 2016 | $650,000 | -34.5% | 13,664 | -47.4% | 0.20% | -49.6% |
| Q4 2015 | $992,000 | -29.0% | 25,995 | -38.9% | 0.39% | -36.2% |
| Q3 2015 | $1,398,000 | -28.5% | 42,566 | +49.2% | 0.61% | +17.4% |
| Q1 2015 | $1,954,000 | -28.9% | 28,523 | -24.0% | 0.52% | +20.3% |
| Q4 2014 | $2,749,000 | – | 37,506 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |